Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension

被引：0
|
作者：
Sayeh Heidari Nejad
Omar Azzam
Markus P. Schlaich
机构：
[1] The University of Western Australia,Dobney Hypertension Centre, Medical School
[2] Royal Perth Hospital, Royal Perth Hospital Unit and RPH Research Foundation
[3] Royal Perth Hospital,Department of Nephrology
来源：
Current Hypertension Reports | 2023年 / 25卷
关键词：
Resistant hypertension; Endothelin receptor antagonist; Aprocitentan; Chronic kidney disease; Blood pressure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：343 / 352
页数：9
相关论文
共 50 条
  • [1] Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension
    Nejad, Sayeh Heidari
    Azzam, Omar
    Schlaich, Markus P.
    [J]. CURRENT HYPERTENSION REPORTS, 2023, 25 (10) : 343 - 352
  • [2] Aprocitentan and the endothelin system in resistant hypertension
    Clozel, Martine
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 100 (07) : 573 - 583
  • [3] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
  • [4] Aprocitentan Dual endothelin ETA/ETB receptor antagonist Treatment of resistant hypertension
    Warden, B. A.
    Duell, P. B.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (08) : 595 - 611
  • [5] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Angeli, Fabio
    Verdecchia, Paolo
    Reboldi, Gianpaolo
    [J]. CARDIOLOGY AND THERAPY, 2021, 10 (02) : 397 - 406
  • [6] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Fabio Angeli
    Paolo Verdecchia
    Gianpaolo Reboldi
    [J]. Cardiology and Therapy, 2021, 10 : 397 - 406
  • [7] Resistant arterial hypertension: endothelin antagonist aprocitentan convinces
    Franke, Katharina
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (11) : 662 - 662
  • [8] Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension
    Brussee, Janneke M.
    Sidharta, Patricia N.
    Dingemanse, Jasper
    Krause, Andreas
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (03) : 243 - 252
  • [9] Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential
    Xu, Jingjing
    Jiang, Xiaohua
    Xu, Suowen
    [J]. DRUG DISCOVERY TODAY, 2023, 28 (11)
  • [10] Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension
    Boutari, Chrysoula
    Siskos, Fotios
    [J]. LIFE-BASEL, 2023, 13 (03):
12345